Published in Pol Arch Med Wewn on February 01, 1971
Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet (1993) 6.56
Flavobacterium multivorum septicemia in a hemodialyzed patient. J Clin Microbiol (1984) 1.49
Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant (1999) 1.39
Responsiveness to recombinant erythropoietin therapy in end-stage renal disease. An analysis of the predictive value of several biological measurements, including circulating erythroid progenitors. Nephrol Dial Transplant (1992) 1.38
A previously undescribed side effect of icodextrin: overestimation of glycemia by glucose analyzer. Perit Dial Int (1999) 1.32
Pseudomonas paucimobilis peritonitis in patients treated by peritoneal dialysis. J Clin Microbiol (1984) 1.04
Effect of vasopressin on the isolated human collecting duct. Nature (1974) 0.89
Campylobacter fetus peritonitis followed by septicaemia in a patient on continuous ambulatory peritoneal dialysis. J Infect (1985) 0.86
Renal biopsy findings in Belgium: a retrospective single center analysis. Acta Clin Belg (2011) 0.85
The referral pattern of patients with ESRD is a determinant in the choice of dialysis modality. Perit Dial Int (1997) 0.84
Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol (2004) 0.84
Intramembranous particle aggregation in toad urinary bladder after vasopressin stimulation. Lab Invest (1979) 0.83
Impaired humoral and cell-mediated immune responses in dialyzed patients after influenza vaccination. Nephron (1983) 0.82
The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure. Br J Clin Pharmacol (1992) 0.82
Severe acute pancreatitis associated with peliosis hepatis in a patient with systemic lupus erythematosus. Acta Gastroenterol Belg (2001) 0.81
Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease. Transplant Proc (2010) 0.81
Hemodynamics of patients with renal failure treated with recombinant human erythropoietin. Clin Nephrol (1989) 0.81
Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant (1989) 0.80
Quantitative ultrasound and dual X-ray absorptiometry measurements of the calcaneus in patients on maintenance hemodialysis. Bone (2000) 0.79
Malignant Mediterranean spotted fever. Report of a case with multiple organ failure, hypocalcemia, and euthyroid sick syndrome. Arch Intern Med (1985) 0.79
The comparison of primordial germ cell populations in embryos of KE and CBA inbred strains of mice. Folia Histochem Cytobiol (1998) 0.78
[Disorders in carbohydrate metabolism in the acute period of myocardial infarction. I. Evaluation of insulin-like activity of serum and cellular uptake of glucose]. Pol Arch Med Wewn (1969) 0.78
Haemodialysis, continuous ambulatory peritoneal dialysis and cellular immunity. Proc Eur Dial Transplant Assoc (1983) 0.78
The referral pattern of end-stage renal disease patients and the initiation of dialysis: a European perspective. Perit Dial Int (1999) 0.78
Adrenergic responses to sustained handgrip in patients with juvenile-onset-type diabetes mellitus. Clin Sci Mol Med (1975) 0.77
[Systemic scleroderma associated to a glomerulonephritis with anti-MPO antibodies: a case report and literature review]. Rev Med Brux (2009) 0.77
Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease. Clin Nephrol (1985) 0.76
Eosinophilia in patients undergoing dialysis. Br Med J (Clin Res Ed) (1981) 0.75
Anaemia and aluminium chelation therapy in dialysis patients. Lancet (1988) 0.75
Red blood cells indices and aluminium toxicity in haemodialysis patients. Proc Eur Dial Transplant Assoc Eur Ren Assoc (1985) 0.75
Continuous ambulatory peritoneal dialysis, protective against developing dialysis-associated amyloid? Nephron (1989) 0.75
Calcium channel blockers as second-line therapy in thiazide-resistant hypertension. Arch Intern Med (1990) 0.75
[5 principles of rational management of diabetes in pregnancy]. Pol Tyg Lek (1982) 0.75
[DNA restriction fragment length polymorphism (RFLP) of insulin and apolipoprotein A-I (apo A-I) genes in patients with diabetes mellitus coexistent with polyendocrinopathy]. Pol Tyg Lek (1987) 0.75
[Mechanisms of the pathogenesis of diabetic macroangiopathy]. Pol Tyg Lek (1982) 0.75
[Comparison of the effectiveness of conventional and intensive insulin therapy in the treatment of diabetes mellitus type 1 in pregnant women or those planning pregnancy]. Pol Tyg Lek (1987) 0.75
[On the subject of medical philosophy: what is medicine today?]. Pol Tyg Lek (1985) 0.75
[Molecular pathology of insulin-dependent diabetes mellitus (type I)]. Pol Tyg Lek (1990) 0.75
[Biological forms of human insulin in the light of methodologic advances]. Pol Arch Med Wewn (1966) 0.75
[Influence of pre-conception pregnancy planning in women with diabetes mellitus I on the number of spontaneous abortions and major congenital malformations in their children]. Ginekol Pol (1999) 0.75
[Algorithm for the differential diagnosis of hyperlipidemia]. Pol Tyg Lek (1985) 0.75
[How to teach medicine, how to educate a physician?]. Pol Tyg Lek (1983) 0.75
[Views with regard to the production and use of sweetening agent substitutes in the diet of patients with diabetes mellitus]. Pol Tyg Lek (1988) 0.75
Disturbances in cabohydrate metabolism at the acute stage of myocardial infarction. Pol Med J (1970) 0.75
[Treatment of hypertension in patients with diabetes mellitus]. Pol Tyg Lek (1984) 0.75
[Methods for the formulation of rural preventive and therapeutic networks in a county]. Zdrow Publiczne (1966) 0.75
[Futuristic remarks on the development of the medical education system]. Pol Tyg Lek (1983) 0.75
[Pathophysiologic basis for obesity in diabetes type II]. Pol Tyg Lek (1995) 0.75
[Microcirculatory evaluation of the early diabetic foot syndrome using laser doppler]. Pol Merkur Lekarski (1997) 0.75
[Effect of pectins on glucose tolerance and insulinemia (IRI) in patients with diabetes mellitus type 2 associated with obesity]. Pol Tyg Lek (1984) 0.75
[Pathophysiology of diabetes mellitus type 2 and the mechanism of action and indications for using hypoglycemic sulfonylurea derivatives]. Pol Tyg Lek (1985) 0.75
[Prospective studies of diabetic retinopathy in a cohort of patients with type II diabetes mellitus]. Pol Merkur Lekarski (1997) 0.75
Computation of the number of diabetics, as well as of diabetic genotypes and of the frequency of diabetic alleles in the Polish population above 14 years of age. Pol Med J (1971) 0.75
[Efficacy and tolerance of axetil cefuroxime for treatment of chronic urinary tract infection relapse in patients with diabetes mellitus]. Pol Tyg Lek (1996) 0.75
[Relative effectiveness of tolbutamide, chlorpropamide and gliclazide]. Pol Tyg Lek (1992) 0.75
[Determining the effect of a pectin-enriched standard diabetic diet on diurnal blood glucose profiles and serum insulin (IRI) levels in diabetes mellitus type 2]. Pol Tyg Lek (1984) 0.75
[Prostaglandins, islands of Langerhans and glucose homeostasis]. Pol Tyg Lek (1984) 0.75
[Permissible physical effort criteria in juvenile diabetes]. Pol Arch Med Wewn (1974) 0.75
[Classification and epidemiology of arterial hypertension in patients with diabetes mellitus]. Pol Tyg Lek (1984) 0.75
[Problems of the philosophy of medicine: who is responsible for health?]. Pol Tyg Lek (1985) 0.75
[Education of patients with diabetes mellitus as a method of treatment]. Pol Tyg Lek (1982) 0.75
[Case for discussion. Problems of diagnosis and clinical management of multi-etiological infection in a patient with collagenosis and long-term corticoid therapy]. Pol Tyg Lek (1983) 0.75
Role of disturbed metabolism of fat tissue cells in the pathogenesis of the diabetogenic effect of obesity in humans. Pol Med Sci Hist Bull (1977) 0.75
Quality of life after simultaneous pancreas-kidney transplantation. Transplant Proc (2005) 0.75
[Autoimmune polyendocrinopathy in insulin-dependent diabetes mellitus]. Pol Tyg Lek (1987) 0.75
[Basal and reactive renin and aldosterone secretion in arterial hypertension of insulin dependent diabetics]. Pol Tyg Lek (1993) 0.75
[Comparison of the effects of chromatographically purified insulin TZF-Polfa and highly purified insulin Nordisk on insulin-induced lipoatrophy]. Pol Tyg Lek (1987) 0.75
Modification of gas-chromatographic method for blood chlorpropamide determination and evaluation of its use for clinical and pharmacological purposes. Pol J Pharmacol Pharm (1984) 0.75
[Aspects of medical philosophy: medical intervention and the system of human values]. Pol Tyg Lek (1985) 0.75
[Preventive and therapeutic measures in the pre-hyperglycemic stage of diabetes mellitus]. Pol Tyg Lek (1987) 0.75
Retrospective analysis of cardiovascular outcomes in patients with type 2 diabetes mellitus after the first acute myocardial infarction. Acta Diabetol (2003) 0.75
[Attendance of outpatient departments by the rural population (in 3 counties of the Lublin region during 1963)]. Zdrow Publiczne (1966) 0.75
[Problems of medical philosophy: remarks on the ethics of institutions and medical health care teams]. Pol Tyg Lek (1985) 0.75
[Specificity of drug therapy of hypertension in patients with diabetes mellitus]. Pol Tyg Lek (1989) 0.75
[Social environment and health]. Pol Tyg Lek (1983) 0.75
[Human--medical and philosophical expression]. Pol Tyg Lek (1994) 0.75
[Medical philosophy: humanities in medicine]. Pol Tyg Lek (1985) 0.75
[Study of medicine based on the conceptual structure of science-- using the example of diabetology]. Pol Tyg Lek (1984) 0.75
[Evaluation of the reactivity of the adrenergic system using the isoproterenol test in diabetes mellitus type 1]. Pol Tyg Lek (1987) 0.75
[Computation of the number of diabetics, the determination of recessive genotypes and the incidence of diabetic alleles in the Polish population over the age of 14]. Pol Arch Med Wewn (1970) 0.75
[Philosophical concept of man and medicine]. Pol Tyg Lek (1983) 0.75
Glycosylated hemoglobin (Hb AI) as an indicator of therapy effects in different clinical types of diabetes. J Chronic Dis (1983) 0.75
[Predicting the development of diabetes mellitus type 1]. Pol Tyg Lek (1992) 0.75
[Diagnosis at the patient's bedside - can it be improved?]. Pol Tyg Lek (1983) 0.75
[Immunogenetic mechanisms in the pathogenesis of type 1 diabetes mellitus]. Pol Tyg Lek (1984) 0.75
[Fructosamine levels as an indicator of the glycosylation of serum proteins in diabetes mellitus type 1: clinical significance]. Pol Tyg Lek (1987) 0.75
[Interaction of antitubercular agents. I. Combined action of rifampicin, isonicotinic acid hydrazide, streptomycin and para-aminosalicylic acid on the growth of strains of tubercle bacilli]. Pneumonol Pol (1977) 0.75
[Monotherapy with acebutolol in hypertensive diabetic patients]. Pol Tyg Lek (1990) 0.75
[3-year observation of the effect of sports training on the development of active tissue mass and adipose tissue mass in children in the pre-and post-pubertal periods]. Pediatr Pol (1982) 0.75
[Interdisciplinary aspects of the treatment of hypertension]. Przegl Lek (1989) 0.75
[Pathogenesis and various clinical problems of cardiomyopathy in diabetes mellitus]. Pol Tyg Lek (1985) 0.75
[The self-education aspects of a physician's activity]. Pol Tyg Lek (1983) 0.75
[Patient education in the treatment of diabetes mellitus]. Pol Tyg Lek (1984) 0.75
[From the area of medical philosophy: biological and cultural mechanisms in the development of man and his health]. Pol Tyg Lek (1985) 0.75
[Pathophysiologic basis of arterial hypertension in diabetic patients]. Pol Tyg Lek (1993) 0.75
[Profile of the main risk factors of arteriosclerosis in patients with diabetes mellitus]. Pol Tyg Lek (1992) 0.75
[Role of metabolism regulation disorders in fatty tissue cells in the pathogenesis of diabetogenic effect of obesity in humans]. Pol Arch Med Wewn (1975) 0.75
[Methods of evaluating the effectiveness of conventional treatment of diabetes mellitus]. Pol Tyg Lek (1982) 0.75
[Method of indirect evaluation of the pharmacodynamic properties of new insulin preparations]. Pol Tyg Lek (1985) 0.75